1. Epizyme, Inc. (33 from 158 patents)

2. Envivo Pharmaceuticals, Inc. (12 from 13 patents)

3. Rugen Holdings (cayman) Limited (10 from 10 patents)

4. Forum Pharmaceuticals, Inc. (8 from 9 patents)

5. Ironwood Pharmaceuticals, Inc. (3 from 44 patents)

6. Eragen Biosciences, Inc. (3 from 11 patents)

7. Luminex Corporation (2 from 177 patents)

8. Methylgene, Inc. (2 from 53 patents)

9. Other (1 from 831,952 patents)

10. Novartis Ag (1 from 3,912 patents)

11. Rfe Pharma LLC (1 from 1 patent)

12. Rugen Holdings Limited (0 patent)

1. 11834455 - Carm1 inhibitors and uses thereof

2. 11752155 - Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

3. 11512053 - Arginine methyltransferase inhibitors and uses thereof

4. 11185531 - Arginine methyltransferase inhibitors and uses thereof

5. 11136328 - 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists

6. 11000526 - Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders

7. 10800743 - Arginine methyltransferase inhibitors and uses thereof

8. 10632103 - Arginine methyltransferase inhibitors and uses thereof

9. 10633389 - CARM1 inhibitors and uses thereof

10. 10584127 - 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists

11. 10420768 - Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists

12. 10294230 - 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists

13. 10227307 - PRMT1 inhibitors and uses thereof

14. 10221182 - 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists

15. 10118931 - CARM1 inhibitors and uses thereof